{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:58:25Z","timestamp":1757624305441,"version":"3.44.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020097","name":"Foundation for Opioid Response Efforts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.dadr.2024.100222","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T15:24:02Z","timestamp":1708615442000},"page":"100222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Leveraging prescription monitoring program data to evaluate the implementation of buprenorphine telehealth flexibilities: An interrupted time series analysis in Texas"],"prefix":"10.1016","volume":"10","author":[{"given":"Whanhui","family":"Chi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chijioke","family":"Okeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abofazl","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler J.","family":"Varisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dadr.2024.100222_bib1","unstructured":"DEA SAMHSA Buprenorphine Telemedicine. (2020). \u3008https:\/\/www.deadiversion.usdoj.gov\/coronavirus.html\u3009"},{"issue":"1","key":"10.1016\/j.dadr.2024.100222_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/08897077.2011.611460","article-title":"Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions","volume":"33","author":"Friedmann","year":"2012","journal-title":"Subst. Abus."},{"key":"10.1016\/j.dadr.2024.100222_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104878","article-title":"Telehealth utilization during the Covid-19 pandemic: a systematic review","volume":"138","author":"Garfan","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.dadr.2024.100222_bib4","unstructured":"Gliadkovskaya, A. (2022). Walmart has a new policy denying some telehealth prescriptions for controlled drugs. It's implicating patients in recovery. Fierce Healthcare. \u3008https:\/\/www.fiercehealthcare.com\/digital-health\/new-policy-walmart-denies-telehealth-prescriptions-without-person-visit\u3009"},{"issue":"2","key":"10.1016\/j.dadr.2024.100222_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1037\/a0022776","article-title":"Facilitators and barriers in implementing buprenorphine in the veterans health administration","volume":"25","author":"Gordon","year":"2011","journal-title":"Psychol. Addict. Behav."},{"issue":"23","key":"10.1016\/j.dadr.2024.100222_bib6","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1001\/jama.2020.21512","article-title":"Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic","volume":"324","author":"Huskamp","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.dadr.2024.100222_bib7","article-title":"Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: an interrupted time series design","volume":"6","author":"Roy","year":"2023","journal-title":"Drug Alcohol Depend. Rep."},{"key":"10.1016\/j.dadr.2024.100222_bib8","unstructured":"SAMHSA. (2021). Telehealth for the Treatment of Serious Mental Illness and Substance Use Disorders. Substance Abuse and Mental Health Services Administration. \u3008https:\/\/store.samhsa.gov\/sites\/default\/files\/pep21-06-02-001.pdf\u3009"},{"issue":"2)","key":"10.1016\/j.dadr.2024.100222_bib9","article-title":"A qualitative assessment of circumstances surrounding drug overdose deaths during the early stages of the COVID-19 pandemic","author":"Tanz","year":"2022","journal-title":"SUDORS Data Brief."},{"key":"10.1016\/j.dadr.2024.100222_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"\u2018Red Flags\u2019 and \u2018Red Tape\u2019: telehealth and pharmacy-level barriers to buprenorphine in the United States","volume":"105","author":"Textor","year":"2022","journal-title":"Int. J. Drug Policy"},{"issue":"6","key":"10.1016\/j.dadr.2024.100222_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000756","article-title":"Impact of COVID-19 related policy changes on buprenorphine dispensing in Texas","volume":"14","author":"Thornton","year":"2020","journal-title":"J. Addict. Med"},{"issue":"6","key":"10.1016\/j.dadr.2024.100222_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000756","article-title":"Impact of COVID-19 related policy changes on buprenorphine dispensing in Texas","volume":"14","author":"Thornton","year":"2020","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.dadr.2024.100222_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108272","article-title":"Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic","volume":"124","author":"Wang","year":"2021","journal-title":"J. Subst. Abus. Treat."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724624000064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724624000064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:33:41Z","timestamp":1757421221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724624000064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":13,"alternative-id":["S2772724624000064"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2024.100222","relation":{},"ISSN":["2772-7246"],"issn-type":[{"type":"print","value":"2772-7246"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging prescription monitoring program data to evaluate the implementation of buprenorphine telehealth flexibilities: An interrupted time series analysis in Texas","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2024.100222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100222"}}